Safety of vaccine adjuvants: Focus on autoimmunity

Vaccine

Volumn 33, Issue 13, 2015, Pages 1507-1514

  van der Laan, Jan Willem ^a   Gould, Sarah ^b   Tanir, Jennifer Y ^c  

^a MEDICINES EVALUATION BOARD   (Netherlands)

^b SANOFI PASTEUR   (France)

^c ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

Author keywords

Animal models; Autoimmunity; Safety; Vaccine adjuvants; Vaccines

Indexed keywords

BIOLOGICAL MARKER; INFLUENZA VACCINE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; VACCINE; WART VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL STUDY; CONFERENCE PAPER; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EMULSION; GENETIC PREDISPOSITION; HUMAN; IMMUNOGENICITY; MEDICAL SOCIETY; MOLECULAR MIMICRY; NONHUMAN; PARASITE LOAD; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; SPECIES DIFFERENCE; ANIMAL; ANIMAL MODEL; IMMUNOLOGY; ORGANIZATION;

ACADEMIES AND INSTITUTES; ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; BIOMARKERS; HUMANS; MODELS, ANIMAL; RISK ASSESSMENT; VACCINES;

EID: 84924959988     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.073     Document Type: Conference Paper

References (50)

1. Sesardic D., Dobbelaer R. European Union regulatory developments for new vaccine adjuvants and delivery systems. Vaccine 2004, 22(19):2452-2456.
2. Montomoli E., Piccirella S., Khadang B., Mennitto E., Camerini R., De Rosa A. Current adjuvants and new perspectives in vaccine formulation. Expert Rev Vaccines 2011, 10(7):1053-1061.
3. Perricone C., Colafrancesco S., Mazor R.D., Soriano A., Agmon-Levin N., Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun 2013, 47:1-16.
4. Force N.N.T. National narcolepsy task force interim report 2011, 1-25. National Insitute for Health and Welfare, Finland.
5. Benstetter M., Haubenreisser S. European Medicines Agency reviews further data on narcolepsy and possible association with Pandemrix. 2011, European Medicines Agency.
6. Rioux J.D., Abbas A.K. Paths to understanding the genetic basis of autoimmune disease. Nature 2005, 435(7042):584-589.
7. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006, 6(11):823-835.
8. Workshop on Adjuvants and Vaccines: Focus on Autoimmunity. 2012; Available from: http://www.hesiglobal.org/files/public/Committees/Vaccines%20and%20Adjuvants/Program_HESI_Workshop_October%202012_.pdf.
9. Schijns V.E., Lavelle E.C. Trends in vaccine adjuvants. Expert Rev Vaccines 2011, 10(4):539-550.
10. O'Hagan D.T., Ott G S, De Gregorio E., Seubert A. The mechanism of action of MF59-an innately attractive adjuvant formulation. Vaccine 2012, 30(29):4341-4348.
11. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol 2010, 11(5):373-384.
12. Verstraeten T., Descamps D., David M.P., Zahaf T., Hardt K., Izurieta P., et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvated vaccines. Vaccine 2008, 26(51):6630-6638.
13. Fenu A., Caturegli P. Definition of autoimmune disease 2008, Available from http://autoimmune.pathology.jhmi.edu/whatis_disease.cfm [cited December 2013].
14. Klein N.P., Ray P., Carpenter D., Hansen J., Lewis E., Fireman B., et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 2010, 28(4):1062-1068.
15. Rose N.R., Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993, 14(9):426-430.
16. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005, 23(30):3876-3886.
17. Lee B.H., Gauna A.E., Pauley K.M., Park Y.J., Cha S. Animal models in autoimmune diseases: lessons learned from mouse models for Sjogren's syndrome. Clin Rev Allergy Immunol 2012, 42(1):35-44.
18. Baradkar V., Samal B., Mali S.A., Kulkarni K., Shastri J. Acanthamoeba on Sabouraud's agar from a patient with keratitis. Trop Parasitol 2011, 1(2):141-142.
19. PUBMED. [Database search]; Available from: [cited 2013]. http://www.ncbi.nlm.nih.gov/pubmed/?term=adjuvant+and+animal+model+and+autoimmune.
20. Jansen T., Hofmans M.P., Theelen M.J., Schijns V.E. Structure-activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses. Vaccine 2005, 23(8):1053-1060.
21. Carlson B.C., Jansson A.M., Larsson A., Bucht A., Lorentzen J.C. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2000, 156(6):2057-2065.
22. Holm B.C., Lorentzen J.C., Bucht A. Adjuvant oil induces waves of arthritogenic lymph node cells prior to arthritis onset. Clin Exp Immunol 2004, 137(1):59-64.
23. Shevach E.M. Animal models for autoimmune and inflammatory disease, in Current Protocols in Immunology 2001, John Wiley & Sons, Inc.
24. European Medicines Agency, European Public Assessment Report-Pandemrix. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000832/WC500038121.pdf.
25. European Medicines Agency, European Public Assessment Report-Aflunov, 2013, Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002094/WC500101080.pdf.
26. European Medicines Agency, European Public Assessment Report-Humenza., 2013, Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001202/WC500094348.pdf.
27. Cannon G.W., Woods M.L., Clayton F., Griffiths M.M. Induction of arthritis in DA rats by incomplete Freund's adjuvant. J Rheumatol 1993, 20(1):7-11.
28. Satoh M., Reeves W.H. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med 1994, 180(6):2341-2346.
29. Kuroda Y., Akaogi J., Nacionales D.C., Wasdo S.C., Szabo N.J., Reeves W.H., et al. Distinctive patterns of autoimmune response induced by different types of mineral oil. Toxicol Sci 2004, 78(2):222-228.
30. Kuroda Y., Nacionales D.C., Akaogi J., Reeves W.H., Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 2004, 58(5):325-337.
31. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25(3):417-428.
32. Devaraj S., Tobias P., Kasinath B.S., Ramsamooj R., Afify A., Jialal I. Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol 2011, 31(8):1796-1804.
33. Wen L., Ley R.E., Volchkov P.V., Stranges P.B., Avanesyan L., Stonebraker A.C., et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008, 455(7216):1109-1113.
34. Lee A.S., Ghoreishi M., Cheng W.K., Chang T.Y., Zhang Y.Q., Dutz J.P. Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse. Diabetologia 2011, 54(6):1407-1416.
35. Tektonidou M.G., Ward M.M. Validation of new biomarkers in systemic autoimmune diseases. Nat Rev Rheumatol 2011, 7(12):708-717.
36. Prince H.E. Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers 2005, 10(Suppl 1):S44- 9.
37. van Herwijnen M.J., Wieten L., van der Zee R., van Kooten P.J., Wagenaar-Hilbers J.P., Hoek A., et al. Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis. Proc Natl Acad Sci USA 2012, 109(35):14134-14139.
38. Kulkarni R., Behboudi S., Sharif S. Insights into the role of toll-like receptors in modulation of T cell responses. Cell Tissue Res 2011, 343(1):141-152.
39. Dai R., Ahmed S.A. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res 2011, 157(4):163-179.
40. Reeves W.H., Lee P.Y., Weinstein J.S., Satoh M., Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 2009, 30(9):455-464.
41. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009, 18(13):1217-1225.
42. Shoenfeld Y., Agmon-Levin N. 'ASIA'-autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36(1):4-8.
43. Shoaib B.O., Patten B.M., Calkins D.S. Adjuvant breast disease: an evaluation of 100 symptomatic women with breast implants or silicone fluid injections. Keio J Med 1994, 43(2):79-87.
44. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012, 7(3):e33536.
45. Wijnans L., Lecomte C., de Vries C., Weibel D., Sammon C., Hviid A., et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A (H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013, 31(8):1246-1254.
46. Miller E., Andrews N., Stellitano L., Stowe J., Winstone A.M., Shneerson J., et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013, 346:pf794.
47. O'Flanagan D., Barret A.S., Foley M., Cotter S., Bonner C., Crowe C., Lynch B., et al. Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine: Ireland April 2009-December 2010. Euro Surveill 2014, 19(17):15-25.
48. Underwood E. Immunology. Key narcolepsy-influenza vaccine findings retracted. Science 2014, 345(6196):p498.
49. Pellegrini M., Nicolay U., Lindert K., Groth N., Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009, 27(49):6959-6965.
50. Rasmussen T.A., Jørgensen M.R., Bjerrum S., Jensen-Fangel S., Støvring H., Østergaard L, et al. Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. BMJ 2012, 345.